|

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

RECRUITINGN/ASponsored by University Hospital, Toulouse
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Toulouse
Started2022-02-01
Est. completion2026-02
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05209776

Summary

The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* For cases:

  * Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
  * Admitted for right ventricle electrophysiologic mapping
* For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.

Exclusion Criteria:

* Diagnostic of systemic chronic inflammatory disease
* Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
* Taking immunosuppressant or immunomodulating medications

Conditions3

Arrhythmogenic Right Ventricular DysplasiaCancerHeart Disease

Browse More Trials

Cancer trialsHeart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.